Consistently, we observed higher proportions (Fig. 4d) and absolute numbers (Fig. 4e) of OT-1 T cells overexpressing PGC-1α present at the tumor site, which tended to be further potentiated when combined with αPD-1 treatment. The gene discussed is PPARGC1A; the disease is neoplasm.